PALO ALTO, Calif., September 09, 2022--Guardant Health introduces GuardantINFINITY, a smart liquid biopsy providing multi-dimensional insights to advance cancer research & drug development.
PALO ALTO, Calif., September 06, 2022--Guardant Health will showcase data at ESMO 2022 demonstrating the utility of its portfolio of blood tests for advanced-stage cancer patients.
Guardant Health announced that it has increased its cooperation with that pharmaceutical company, the sprawling Merck & Co. (NYSE: MRK). The deal centers on the former company's GuardantINFORM diagnostics platform, which Merck will use to help develop the products in its precision oncology pipeline. Guardant data scientists will work closely with their Merck colleagues to disseminate the data supplied by the platform, the company said.